ATE505488T1 - Modulator von coagulationskaskaden und fibrinolytischen kaskaden - Google Patents

Modulator von coagulationskaskaden und fibrinolytischen kaskaden

Info

Publication number
ATE505488T1
ATE505488T1 AT06736060T AT06736060T ATE505488T1 AT E505488 T1 ATE505488 T1 AT E505488T1 AT 06736060 T AT06736060 T AT 06736060T AT 06736060 T AT06736060 T AT 06736060T AT E505488 T1 ATE505488 T1 AT E505488T1
Authority
AT
Austria
Prior art keywords
cascades
modulator
fibrinolytic
coagulation
wound
Prior art date
Application number
AT06736060T
Other languages
English (en)
Inventor
James Morrissey
Stephanie Smith
Roberto Docampo
Nicola Mutch
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE505488T1 publication Critical patent/ATE505488T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06736060T 2005-03-04 2006-02-23 Modulator von coagulationskaskaden und fibrinolytischen kaskaden ATE505488T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65877605P 2005-03-04 2005-03-04
PCT/US2006/006642 WO2006096345A2 (en) 2005-03-04 2006-02-23 Coagulation and fibrinolytic cascades modulator

Publications (1)

Publication Number Publication Date
ATE505488T1 true ATE505488T1 (de) 2011-04-15

Family

ID=36648781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736060T ATE505488T1 (de) 2005-03-04 2006-02-23 Modulator von coagulationskaskaden und fibrinolytischen kaskaden

Country Status (8)

Country Link
US (2) US7682808B2 (de)
EP (1) EP1869082B1 (de)
JP (1) JP2008531692A (de)
CN (1) CN101184775A (de)
AT (1) ATE505488T1 (de)
CA (1) CA2600907C (de)
DE (1) DE602006021290D1 (de)
WO (1) WO2006096345A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151533A (zh) * 2005-02-16 2008-03-26 伊利诺斯大学理事会 基于金属螯合脂质的促凝血剂
US7682808B2 (en) 2005-03-04 2010-03-23 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
JP5073270B2 (ja) 2006-11-14 2012-11-14 シスメックス株式会社 凝固検査用試薬及びその製造方法
US20090047366A1 (en) * 2007-08-15 2009-02-19 Bedard Robert L Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants
US8821861B2 (en) 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
DE102007062323A1 (de) * 2007-12-21 2009-06-25 Siemens Healthcare Diagnostics Products Gmbh Langzeitstabiles Thromboplastin-Reagenz
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
SI2379096T1 (sl) * 2008-12-19 2020-03-31 Baxalta GmbH Zaviralci TFPI in postopki uporabe
MX2011006501A (es) 2008-12-22 2011-07-12 Novo Nordisk As Anticuerpos contra inhibidor de la via de factor de tejido.
EA201892184A1 (ru) 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
CA2793465C (en) 2010-03-19 2022-06-14 Baxter International Inc. Tfpi inhibitors and methods of use
EP2621548B1 (de) 2010-09-27 2017-05-24 Tissue Regenix Limited Azelluläre vaskuläre produkte
NZ724133A (en) 2012-03-21 2020-07-31 Baxalta Inc Tfpi inhibitors and methods of use
FI3659627T3 (fi) 2013-03-08 2024-03-27 Univ California Polyfosfaattifunktionalisoituja epäorgaanisia nanopartikkeleita hemostaattisina koostumuksina ja käyttömenetelmiä
DE102013222223A1 (de) * 2013-10-31 2015-04-30 Bk Giulini Gmbh Blutstillendes Mittel enthaltend kristallines Polyphosphat
US9408871B2 (en) * 2013-11-08 2016-08-09 The University Of British Columbia Methods for inhibiting complement activation and uses thereof
WO2016049250A1 (en) 2014-09-24 2016-03-31 The Board Of Trustees Of The University Of Illinois Artificial platelets for treating catastrophic bleeding
JP7101351B2 (ja) * 2016-04-28 2022-07-15 シスメックス株式会社 血液検体の分析方法、血液検体分析用試薬及び試薬キット、並びに血液検体分析装置
US11519917B2 (en) 2017-04-13 2022-12-06 The Regents Of The University Of Michigan Assay for quantifying polyphosphates
PL3897758T3 (pl) * 2018-12-20 2023-05-29 Bk Giulini Gmbh Środek do leczenia krwawiących ran
CN111856043A (zh) * 2020-08-28 2020-10-30 保定天岳生物工程有限公司 一种凝血酶原时间检测试剂盒

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852341A (en) * 1954-08-20 1958-09-16 Victor Chemical Works Calcium polyphosphate and method of producing the same
DE1617733A1 (de) 1967-03-31 1971-04-08 Penicillin Ges Dauelsberg & Co Verfahren zur Herstellung eines Praeparates fuer die Behandlung schwer heilender Wunden und Eiterungen
ES431736A1 (es) * 1973-11-13 1977-05-16 Behringwerke Ag Procedimiento para la preparacion de un agente para diagnos-tico para el proposito de efectuar el control de la capaci- dad de coagulacion de la sangre.
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
DE3150596A1 (de) * 1981-12-21 1983-06-30 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von gewebsthromboplastin
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
DE3413311A1 (de) * 1984-04-09 1985-10-17 Behringwerke Ag, 3550 Marburg Reagenz zur bestimmung der thromboplastinzeit
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
DE3516579A1 (de) * 1984-11-19 1986-05-22 Boehringer Mannheim Gmbh, 6800 Mannheim Gerinnungstest auf teststreifen
US4874766A (en) * 1986-09-22 1989-10-17 Janssen Pharmaceutica N.V. Method of promoting wound-healing
JP2851627B2 (ja) * 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
US4865984A (en) * 1988-02-08 1989-09-12 Mount Sinai School Of Medicine Of The City University Of New York Dynamic continuous flow enzyme reactor
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
EP0396733B1 (de) * 1988-11-23 1994-01-05 Baxter Diagnostics Inc. Ausscheidungsverfahren für die herstellung von thromboplastinreagenzien
US5270451A (en) * 1988-11-23 1993-12-14 Baxter Diagnostics Inc. Extraction method for preparing thromboplastin reagents
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
NL8902406A (nl) * 1989-09-27 1991-04-16 Hendrik Coenraad Hemker Prof D Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.
US5169786A (en) * 1989-12-19 1992-12-08 Ortho Diagnostic Systems, Inc. Method of determining levels of extrinsic and intrinsic clotting factors and protein c
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5254350A (en) * 1991-07-22 1993-10-19 Helena Laboratories Corporation Method of preparing a thromboplastin extract
US5338538A (en) * 1991-07-29 1994-08-16 Pfizer Inc Prebrushing pyrophosphate-containing liquid oral compositions
DE69224622T2 (de) 1991-10-04 1998-11-05 Dade Behring, Inc., Deerfield, Ill. Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden
WO1993022453A1 (en) * 1992-04-27 1993-11-11 Avocet Medical, Inc. Test article and method for performing blood coagulation assays
US5580744A (en) * 1992-04-27 1996-12-03 Avocet Medical, Inc. Test article and method for performing blood coagulation assays
US5358853A (en) * 1992-08-03 1994-10-25 Akzo Av Liquid thromboplastin reagent
DE4243729A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
ATE202633T1 (de) * 1994-04-28 2001-07-15 Dade Behring Inc Kalibrator für prothrombin-zeit-assays
US5418141A (en) * 1994-05-06 1995-05-23 Avocet Medical, Inc. Test articles for performing dry reagent prothrombin time assays
AT403437B (de) 1995-02-15 1998-02-25 Immuno Ag Physiologisch aktive gewebefaktor-präparation
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
DE69637012T2 (de) * 1995-06-07 2009-01-08 G.D. Searle Llc (N.D.Ges.D. Staates Delaware) Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers
US5691380A (en) * 1995-06-29 1997-11-25 The Procter & Gamble Company Stable n-acetylcysteine compositions and methods for treating human skin therewith
DE69719834T2 (de) * 1996-04-24 2003-11-20 Pfizer Inc., New York Dentalwerkstoffe enthaltend Cyclodextrine und phenolische Verbindungen
US5858724A (en) 1996-07-16 1999-01-12 Pel-Freez Recombinant rabbit tissue factor
US5787901A (en) * 1997-01-28 1998-08-04 Akzo Nobel N.V. Method for the measurement of blood coagulation properties with absorbent materials
AT405692B (de) 1997-03-27 1999-10-25 Immuno Ag Reagens zur bestimmung der aptt
US6100072A (en) * 1997-04-23 2000-08-08 Instrumentation Laboratory S.P.A. Recombinant rabbit tissue factor based prothrombin time reagent
DE19720853A1 (de) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
US5968528A (en) * 1997-05-23 1999-10-19 The Procter & Gamble Company Skin care compositions
US6258368B1 (en) * 1997-06-04 2001-07-10 The Procter & Gamble Company Antimicrobial wipes
JP4176157B2 (ja) * 1997-07-23 2008-11-05 株式会社トクヤマ 凝固パラメーターの決定方法
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
DE19749197A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Bestimmung des antikoagulatorischen Potentials einer Probe
US5928174A (en) * 1997-11-14 1999-07-27 Acrymed Wound dressing device
US6207419B1 (en) 1998-02-27 2001-03-27 The University Of North Carolina At Chapel Hill Thrombin inhibitory agents and methods of using same
DE19811016A1 (de) 1998-03-13 1999-09-16 Dade Behring Marburg Gmbh Gebrauchsfertiges Prothrombinzeitreagenz auf der Basis von rekombinantem Gewebsfaktor
US6194394B1 (en) * 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
DE69928961T2 (de) * 1998-10-07 2006-07-13 Trinity Biotech Manufacturing Ltd. Thromboplastin-reagenzien und verfahren zur herstellung und anwendung derselben
US6451610B1 (en) * 1999-04-14 2002-09-17 International Technidyne Corporation Method and apparatus for coagulation based assays
US6284802B1 (en) 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
AUPQ002399A0 (en) 1999-04-28 1999-05-20 Australian National University, The Model membrane systems
US6733985B1 (en) * 1999-05-19 2004-05-11 International Technidyne Corporation Preparation of stable liquid and dried synthetic prothrombin time reagents
CA2377181C (en) * 1999-07-22 2008-01-22 Lulu S. Henson Antimicrobial polyphosphates in food processing
US6248353B1 (en) * 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US6187347B1 (en) 2000-02-09 2001-02-13 Ecosafe, Llc. Composition for arresting the flow of blood and method
EP1281089A1 (de) * 2000-02-23 2003-02-05 Besst-Test APS Verfahren zum korrelieren der blutkoagulationsaktivität mit markierern in körperflüssigkeiten wie z.b. urin
KR100338491B1 (ko) * 2000-03-30 2002-05-30 채수경 인중합체로 된 흉터 억제 및 상처 회복 촉진제
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US7622437B2 (en) 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
EP1229048A1 (de) * 2001-02-05 2002-08-07 International Reagents Corporation Thromboplastinreagenz und Verfahren zu dessen Herstellung
US6596543B2 (en) * 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
US20030064414A1 (en) * 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
CN1607958A (zh) * 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
EP1458407A1 (de) * 2001-12-21 2004-09-22 Novo Nordisk A/S Flüssige zusammensetzung von modifizierten faktor-vii-polypeptiden
US6746872B2 (en) * 2002-01-16 2004-06-08 Lifescan, Inc. Control compositions and methods of use for coagulation tests
WO2004003550A2 (en) * 2002-06-28 2004-01-08 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
US7049087B2 (en) * 2002-11-05 2006-05-23 Lifescan, Inc. Method for manufacturing a tissue factor-based prothrombin time reagent
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
KR100592513B1 (ko) 2003-06-12 2006-06-23 김홍렬 인중합체를 유효성분으로 함유하는 항산화용 약학적조성물 또는 건강식품
EP1682863B1 (de) 2003-09-22 2012-07-04 University Of North Carolina At Chapel Hill Lösliche phospholipide zur verwendung in gerinnungsfaktortests
US7148067B2 (en) 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
CN101151533A (zh) 2005-02-16 2008-03-26 伊利诺斯大学理事会 基于金属螯合脂质的促凝血剂
US7682808B2 (en) 2005-03-04 2010-03-23 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
US7622737B2 (en) 2007-07-11 2009-11-24 International Business Machines Corporation Test structures for electrically detecting back end of the line failures and methods of making and using the same
US20090053288A1 (en) 2007-08-20 2009-02-26 Eskridge Jr E Stan Hemostatic woven fabric
US8821861B2 (en) 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant

Also Published As

Publication number Publication date
CN101184775A (zh) 2008-05-21
US7682808B2 (en) 2010-03-23
EP1869082B1 (de) 2011-04-13
WO2006096345A2 (en) 2006-09-14
US9597375B2 (en) 2017-03-21
CA2600907A1 (en) 2006-09-14
CA2600907C (en) 2016-06-28
JP2008531692A (ja) 2008-08-14
US20100143492A1 (en) 2010-06-10
WO2006096345A3 (en) 2006-11-30
DE602006021290D1 (de) 2011-05-26
EP1869082A2 (de) 2007-12-26
US20060198837A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
ATE505488T1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
SE0301882D0 (sv) New use I
NI200900205A (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c.
SE0301886D0 (sv) New use V
SE0301888D0 (sv) New use VII
NZ574653A (en) Solid dressing for treating wounded tissue
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
CY1113705T1 (el) Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων
DE602005019319D1 (de) Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
Sterling et al. Hemostasis in burn surgery—a review
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
DK1558265T3 (da) Anvendelse af dropspirenon til behandling af hypertension
CL2009000367A1 (es) Compuestos derivados de tiofen-amidas, inhibidores de los factores de la coagulacion xa y trombina; procedimiento de preparacion; composicion farmaceutica; y uso en trastornos cardiovasculares, enfermedades tromboembolicas o restenosis.
EP2481429A3 (de) MMP-Aktivierte Gefässschädigende Mittel
BR112012028153A2 (pt) composição farmacêutica e método para o tratamento de hipertensão
ATE450187T1 (de) Verhinderung von hautlappennekrose in der plastischen chirurgie
EP2049101A4 (de) Substituiertes 4-aryl-chromen als caspasen-aktivator, apoptose-induktor und antivaskuläres mittel sowie seine verwendung
SE0301883D0 (sv) New use II
SE0301885D0 (sv) New use IV
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SE0301884D0 (sv) New use III
SE0201662D0 (sv) Pharmaceutical combination
WO2006083667A3 (en) Treatment of oxygen induced inflammatory tissue injury
DK1351705T3 (da) Sammensætninger til behandling af blödning med aktiveret faktor VIIA i kombinantion med fibrinogen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties